BeiGene's hematology CMO is on her way out amid market turmoil
After six years in the role, BeiGene’s hematology CMO has announced her upcoming departure.
The biotech kept it short in an 8-K filed yesterday, but here’s what we know: Jane Huang, featured in our Top 20 Women in Biopharma special report just three months ago, tendered her resignation and gave 30 days notice on Wednesday — and she will be no longer working as an employee after April 3. No reason was given for her departure, and there has been no mention of who her replacement will be.
Huang came to BeiGene in 2016 after a short run at Acerta as their VP and head of clinical development. Before Acerta, she had a 10-year stint at Genentech as a medical director.
After Huang officially resigns on April 3rd, she will be a consultant for BeiGene for a few months until November 14. And that might come in handy with the churning of R&D, the light of a historic bear market and what’s expected up ahead for its BTK inhibitor Brukinsa.
Back in September, the FDA approved Brukinsa for rare blood cancer Waldenström’s Macroglobulinemia as BeiGene looked at rapidly ramping up its US expansion plans.
And after showing Phase III data in first-line chronic lymphocytic leukemia (CLL) or small lymphocytic leukemia (SLL) at ASH back in November, Huang told Endpoints News that while the company isn’t saying when it expects to file for regulatory approvals, it’s working to get Brukinsa to patients in “as many countries as possible.”
BeiGene announced last week that Brukinsa is now awaiting a PDUFA date of Oct. 22 for both CLL and SLL indications.
Huang’s departure is one of the newest developments happening in many biotech C-suites — with somewhat of a small biotech CEO exodus, including Tillman Gerngross from Adagio, Gemini Therapeutics’ CEO Jason Meyenberg, and Deepa Prasad resigned from troubled Alzheimer’s player vTv Therapeutics.